A. Patané, C. Poleri, L. Vila, Basile Florencia, Guman Gabriela, Raya Mercedes, Rivero Hector, Rosales Adolfo, Rosenberg Moises
{"title":"Thymomas: Analysis of Histological Subtypes and Staging in Patients with Surgical Treatment in Two Reference Centers in Argentina","authors":"A. Patané, C. Poleri, L. Vila, Basile Florencia, Guman Gabriela, Raya Mercedes, Rivero Hector, Rosales Adolfo, Rosenberg Moises","doi":"10.31487/j.cor.2021.08.01","DOIUrl":null,"url":null,"abstract":"Background: Thymomas are a heterogeneous group of tumors which represent the most frequent tumor of \nthe anterior mediastinum. \nAims: To describe the clinical, histological, surgical and oncological characteristics of a cohort of patients \nwith a diagnosis of thymoma surgically treated in two centers in Argentina and to evaluate the possibility \nof retrospectively implementing the 8th edition of TNM staging. \nMaterials and Methods: 180 patients with thymoma surgically treated over a period of 41 years were \nstudied. The following variables were analysed: age, sex, presence of myasthenia gravis at diagnosis, \nMasaoka staging (1994), TNM staging of thymus tumors, Histological classification (WHO 2015), \nneoadjuvant treatment with chemotherapy, post-operative radiation treatment and clinical evolution of \nmyasthenia gravis defined according to the modified Osserman classification. \nResults: 96 men and 84 women were analysed. Median age 51 years (range 13-85). 85% of the patients \nanalysed came from the public sphere. When analysing the institutional distribution by Masaoaka-Koga \nstage and TNM, a higher proportion of stages I was observed for both staging systems. Most myasthenic \npatients belonged to the WHO B2 histological classification (49%, p=0.04) and 15 patients received \nneoadjuvant treatment prior to surgery to improve the chances of resection, most of them classified as stages \nIII of Masaoka (p=0.002) or IIIa of the TNM stage (p=0.001). 74 (46%) cases received post-operative RT \nwhen they presented Masaoka Koga stages II (p=0.000) and IIIa or more advanced TNM staging (p=0.000). \n76% of the patients presented remission or stability of symptoms after surgical treatment and only 3/6 died \ndue to myasthenic crisis in the immediate post-operative period. \nConclusion: As reported in the literature, we have observed a higher frequency of B2 thymomas and their \nassociation with Myasthenia gravis. The histological criteria of the WHO 2015 classification, based on the \nITMIG recommendations, favour precision in the definition of subtypes. The retrospective implementation \nof the 8th edition of TNM staging highlights the need to standardize protocols for pathological and surgical \nstudies.","PeriodicalId":10487,"journal":{"name":"Clinical Oncology and Research","volume":"52 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Oncology and Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31487/j.cor.2021.08.01","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Thymomas are a heterogeneous group of tumors which represent the most frequent tumor of
the anterior mediastinum.
Aims: To describe the clinical, histological, surgical and oncological characteristics of a cohort of patients
with a diagnosis of thymoma surgically treated in two centers in Argentina and to evaluate the possibility
of retrospectively implementing the 8th edition of TNM staging.
Materials and Methods: 180 patients with thymoma surgically treated over a period of 41 years were
studied. The following variables were analysed: age, sex, presence of myasthenia gravis at diagnosis,
Masaoka staging (1994), TNM staging of thymus tumors, Histological classification (WHO 2015),
neoadjuvant treatment with chemotherapy, post-operative radiation treatment and clinical evolution of
myasthenia gravis defined according to the modified Osserman classification.
Results: 96 men and 84 women were analysed. Median age 51 years (range 13-85). 85% of the patients
analysed came from the public sphere. When analysing the institutional distribution by Masaoaka-Koga
stage and TNM, a higher proportion of stages I was observed for both staging systems. Most myasthenic
patients belonged to the WHO B2 histological classification (49%, p=0.04) and 15 patients received
neoadjuvant treatment prior to surgery to improve the chances of resection, most of them classified as stages
III of Masaoka (p=0.002) or IIIa of the TNM stage (p=0.001). 74 (46%) cases received post-operative RT
when they presented Masaoka Koga stages II (p=0.000) and IIIa or more advanced TNM staging (p=0.000).
76% of the patients presented remission or stability of symptoms after surgical treatment and only 3/6 died
due to myasthenic crisis in the immediate post-operative period.
Conclusion: As reported in the literature, we have observed a higher frequency of B2 thymomas and their
association with Myasthenia gravis. The histological criteria of the WHO 2015 classification, based on the
ITMIG recommendations, favour precision in the definition of subtypes. The retrospective implementation
of the 8th edition of TNM staging highlights the need to standardize protocols for pathological and surgical
studies.